TrialBlood2015

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia.

Jeff Sharman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.